The USFDA has granted approval to zanubrutinib for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). ##Common adverse reactions##   Decreased neutrophil count (42%) Upper respiratory tract infection (39%) Decreased platelet count (34%) Hemorrhage (30%) ·        Musculoskeletal pain (30%) ·        Second primary malignancies, including non-skin carcinomas (13%) ·        Atrial fibrillation or flutter (3.7%) ·        Grade 3 or higher ventricular arrhythmias (0.2%)## ##Recommended dosage## 160 mg taken orally twice daily or 320 mg taken orally once daily until disease progression or unacceptable toxicity## Clinical evidence from SEQUOIA trial (Figure 1) and ALPINE trial (Figure 2) is summarized below Testing efficacy in patients with treatment-naïve CLL/SLL:   Do you believe zanubrutinib can revolutionize treatment for CLL/SLL?

Share your views by…